Micron Biomedical, Inc. news

Dr. Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. Francis Collins. This summit outlined a path toward innovative, next-generation COVID-19 vaccines and vaccine delivery technologies, featuring leaders on the cutting-edge of research, dis

– Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron’s Microneedle-Based Measles-Rubella Vaccine –

ATLANTA, July 13, 2021 /PRNewswire/ – Micron Biomedical, Inc. (“Micron” or the “Company”), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical trial of its microneedle-based measles-rubella (“MR”) vaccine

Micron Biomedical, Inc. (Micron) was awarded a new research contract by the Centers for Disease Control and Prevention (CDC) to manufacture IRV microneedle patches for future clinical evaluation. Micron and CDC have been collaborating on the development of the IRV microneedle patch for several years. Preclinical studies of the IRV vaccine, developed by the CDC, delivered using Micron’s dissolving microneedle patch technology show that the IRV microneedle patch is immunogenic and safe in

If some of the many thousands of human volunteers needed to test coronavirus vaccines could have been replaced by digital replicas—one of this year’s Top 10 Emerging Technologies—COVID-19 vaccines might have been developed even faster, saving untold lives. Soon virtual clinical trials could be a reality for testing new vaccines and therapies. Other technologies on the list could reduce greenhouse gas emissions by electrifying air travel and enabling sunlight to dire

Under $6.745 Million Grant from the Bill & Melinda Gates Foundation

ATLANTA, Sept. 1, 2020 /PRNewswire/ — Micron Biomedical, Inc. (Micron) recently received a second tranche of funding ($2.6M) to continue clinical development of its microneedle-based technology for measles and rubella vaccination from the Bill & Melinda Gates Foundation. This work leverages Micron’s technology, which has already been successfully evaluated in clinical studies includi

ATLANTA, October 2, 2018 – Micron Biomedical, Inc. (Micron) recently completed a feasibility study with one of its commercial partners, a top-10 pharmaceutical company.  The study consisted of developing a dissolving microneedle patch with specific design attributes to meet the partner’s unique delivery requirements and to assess the microneedle patch in in-vitro and in-vivo experiments.  The study demonstrated the suitability of Micron’s microne

ATLANTA, August 27, 2018 – Micron Biomedical, Inc. (Micron) was awarded a new research contract by the Centers for Disease Control and Prevention (CDC) to continue the development of an IRV-IPV microneedle patch and its GMP manufacturing process.  This new research contract comes after Micron successfully completed a Phase 1 SBIR grant and a research contract with the CDC for the development of a microneedle patch for the administration of inactivated rotavirus vaccine (IRV) and co

ATLANTA, July 23, 2018 – Following the successful completion of a first stage of preclinical development work with one of its commercial partners, a leading clinical stage biotechnology company, Micron Biomedical, Inc. (Micron) signed a new research agreement (RA) with its partner to continue the development of a microneedle patch for delivery of the partner’s API. The new RA includes additional patch design development work as well as in-vitro and in-vivo evaluation of the micron